Court Halts Boehringer’s COPD Inhaler Comparative Claims Vs. GSK Products

GlaxoSmithKline win shows value of going to court as US FDA is less likely to take action against comparative promotions. Court was swayed by GSK survey showing likely harm caused by ‘false and misleading statements not supported by scientific studies.’

Inhaler
Court enjoins Boehringer Ingelheim from making false and misleading statements about GSK's dry powder inhalers

A district court ordered Boehringer Ingelheim Pharmaceuticals Inc. to cease making certain marketing claims that GlaxoSmithKline plc’s dry powder inhalers are not as effective for some patients. The ruling may encourage other companies to take disputes over comparative promotional campaigns to court since the US Food and Drug Administration has become more cautious about pursuing advertising violations.

Last year, GlaxoSmithKline filed suit against BI to halt its marketing campaign for BI’s Respimat slow mist inhaler (SMI), which...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Marketing & Advertising

More from Compliance